Research ArticleEmerging Technologies and Therapeutics
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
Eiichi Araki, Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Jo Satoh, Toyoshi Inoguchi, Jiro Nakamura, Hiroshi Maegawa, Narihito Yoshioka, Yukio Tanizawa, Hirotaka Watada, Hideki Suganami, Shun Ishibashi
DOI: 10.2337/dc17-1589 Published 1 March 2018
Eiichi Araki
1Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
Shizuya Yamashita
2Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
3Rinku General Medical Center, Osaka, Japan
Hidenori Arai
4National Center for Geriatrics and Gerontology, Aichi, Japan
Koutaro Yokote
5Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
Jo Satoh
6Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, Miyagi, Japan
Toyoshi Inoguchi
7Fukuoka Health Promotion Support Center, Fukuoka, Japan
Jiro Nakamura
8Division of Diabetes, Department of Internal Medicine, Aichi Medical University, Aichi, Japan
Hiroshi Maegawa
9Department of Medicine, Shiga University of Medical Science, Shiga, Japan
Narihito Yoshioka
10Division of Diabetes and Endocrinology, Department of Medicine, Sapporo Medical Center, NTT East Corporation, Hokkaido, Japan
Yukio Tanizawa
11Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
Hirotaka Watada
12Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan
Hideki Suganami
13Clinical Data Science Department, Kowa Company, Ltd., Tokyo, Japan
Shun Ishibashi
14Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University, Tochigi, Japan